



## Joint Working Executive Summary

### The Cancer Vanguard Interactive Medicines Optimisation and Compliance Dashboard and Evaluation Framework

In partnership with the Cancer Vanguard this project will develop an 'Interactive Medicines Optimisation and Compliance Dashboard and Evaluation Framework' using the Systemic Anti-Cancer Therapy (SACT) dataset. The dashboard will enable a visual analysis of the underlying dataset and will identify potential sub-optimal use of medicines. It will also facilitate the multi-disciplinary team to review and amend prescribing with respect to utilisation of treatment, where appropriate, to improve patient outcomes.

The second part of the project will be to develop an assessment framework to evaluate the service delivery models used across the Cancer Vanguard (a) from the patient perspective and (b) in terms of the operational and financial impacts for the NHS. The objective is to offer better choice and experience for patients, encouraging treatment compliance/optimisation, whilst understanding the impacts on NHS resources, ideally identifying cost saving or cost neutral options.

#### Potential patient outcomes for this project:

- *Better use of NHS resources*
  - Medicines usage is optimised to improve safety and outcomes, reducing wastage.
  - Clinicians save time in identifying and addressing non-compliance, enabling greater focus on providing high-quality care to patients.
- *Fast identification of sub-optimal medicines use*

The analysis will reveal situations where medicines use has deviated from protocol, so that corrective action can be taken, if appropriate. This will have a potential dual benefit:

  - Improved safety by ensuring that medicines are taken as prescribed.
  - Improved clinical outcomes by ensuring compliance with protocol.
- *Enhancing the understanding of patient experience*
  - By looking at the impact of the service model on patient experience, assessing the practicalities of accessing treatment from the patient perspective.
- *Improving evidence based choice of medicines*
  - By looking at the reasons behind choice and removing non-clinical barriers, such as inconvenience. Sharing good practice across the Cancer Vanguard.
- *Helping to ensure most appropriate use of medicines*
  - By analysing cases of potential sub-optimal medicines usage, to improve safety and outcomes. Optimise patient outcomes by creating efficient and effective patient pathways.
- *Making medicines optimisation part of routine practice*
  - By operationalising the process via dashboard analytics that can be used on an on-going basis and rolled out nationally.

#### Celgene Ltd/the Cancer Vanguard Contribution

All parties have committed resource in support of this Joint Working Project which runs from February to June 2017.

This project is intended as a proof of concept with the Cancer Vanguard, although there is an awareness that this concept is not limited to products/therapies within the Celgene portfolio and may subsequently be broadened to cover additional therapies.